CVS Caremark, FTC settle insulin pricing case for $13B

The FTC settled its antitrust case against CVS Caremark over insulin pricing practices, requiring the PBM to pass rebates to patients at point of sale, delink manufacturer fees from list prices, and increase transparency. The settlement is expected to deliver up to $13 billion in consumer savings over ten years.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.